Ƶ

AHA: Some Statins May Disrupt Sleep

— ORLANDO -- If patients taking simvastatin (Zocor) develop sleep disturbances, changing statins may be a good idea, researchers suggested here.

Ƶ MedicalToday

ORLANDO, Nov. 8 -- If patients taking simvastatin (Zocor) develop sleep disturbances, changing statins may be a good idea, researchers suggested here.


Simvastatin modestly but significantly reduced sleep quality and increased sleep problems compared with pravastatin (Pravachol), according to a large study of subjective sleep measures reported at the American Heart Association meeting.


"This provides tentative corroboration for long-standing concerns that lipophilic statins may affect sleep in some individuals," said Beatrice Golomb, M.D., Ph.D., of the University of California at San Diego, who reported the findings of a study of 1,016 patients.

Action Points

  • Explain to interested patients that the study supports an effect of statins on sleep, particularly lipophilic agents such as simvastatin.
  • This study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary as they have not yet been reviewed and published in a peer-reviewed publication.


Simvastatin is the most lipophilic of the statins, she noted. This may allow the drug to more readily cross the blood-brain barrier and impact serotonin or other sleep-related factors compared with statins such as pravastatin, which is the most hydrophilic.


Among other statins, lovastatin is lipophilic, rosuvastatin (Crestor) may be hydrophilic, and atorvastatin (Lipitor) is considered intermediate.


For patients who develop sleep problems after starting on a statin, "it might be prudent to switch to a different statin," Dr. Golomb said.


Sleep has not generally been reported as an adverse event in large efficacy trials, although case series and smaller trials have indicated insomnia, nightmares and other sleep disturbances may be more common with some statins.


To test sleep outcomes prospectively, the researchers conducted a double-blind trial in which 1,000 men and postmenopausal women were randomized to placebo or equivalent, or modest doses of pravastatin (40 mg) or simvastatin (20 mg).


At baseline, participants had LDL cholesterol in the 115 to 190 mg/dl range, for which statin treatment was considered optional at the time. None had known cardiovascular disease, diabetes, or a fasting blood glucose of 140 mg/dl or higher. None was on statin therapy before enrollment in the study.


Sleep quality and sleep problems were similar between treatment groups at baseline. At six months, sleep quality dropped in all three groups, but there were significant differences between them.


On-treatment sleep quality remained above average with pravastatin and placebo (mean score 15.79 and 15.50 on a 30-point visual analog Leeds scale), whereas it was below average with simvastatin (mean 14.67, P=0.003 versus pravastatin and P=0.026 versus placebo).


Sleep problems worsened during treatment to a greater degree with simvastatin than with pravastatin or placebo (0.21 versus 0.098 and 0.074 on a two-point scale from zero change to much worse). After adjustment for baseline problems with sleep, the differences were significant (P=0.038 versus pravastatin and P=0.007 versus placebo).


Sleep quality was significantly linked to tiredness and irritability, whereas sleep problems were correlated with tiredness, irritability, and cognition (all P<0.001).


More patients taking simvastatin reported sleep as much worse than at baseline than did patients on placebo (P=0.015), and a similar trend was seen compared with pravastatin (P=0.093).


However, the researchers could not pin down what specific sleep changes were occurring.


In an exploratory analysis, there were no differences in unrestful sleep or other characteristics measured. However, nightmares and sleep-disordered breathing were possibilities not measured in the study that have been seen in previous, smaller studies.


Further study is also needed to look prospectively at sleep with other statins, as well as to look at higher doses since other statin-related adverse events are dose dependent, Dr. Golomb said.


The researchers reported no relevant conflicts of interest.

Primary Source

American Heart Association Meeting

Source Reference: Golomb BA, et al "Simvastatin but Not Pravastatin Affects Sleep: Findings from the UCSD Statin Study" AHA Meeting 2007; Abstract 3725.